REGENERON PHARMACEUTICALS INCREGENERON PHARMACEUTICALS INCREGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS INC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪73.64 B‬USD
40.88USD
‪4.41 B‬USD
‪14.20 B‬USD
‪105.38 M‬
Beta (1Y)
0.76
Employees (FY)
‪15.11 K‬
Change (1Y)
‪+1.66 K‬ +12.31%
Revenue / Employee (1Y)
‪940.16 K‬USD
Net income / Employee (1Y)
‪292.11 K‬USD

About Regeneron Pharmaceuticals, Inc.


CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Founded
1988
FIGI
BBG01LGV61Z9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of REGN is 680.10 USD — it has decreased by −36.01% in the past 24 hours. Watch REGENERON PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BVL exchange REGENERON PHARMACEUTICALS INC stocks are traded under the ticker REGN.
REGN stock has fallen by −36.01% compared to the previous week, the month change is a −36.01% fall, over the last year REGENERON PHARMACEUTICALS INC has showed a −32.60% decrease.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC future price: according to them, REGN price has a max estimate of 1,152.00 USD and a min estimate of 575.00 USD. Watch REGN chart and read a more detailed REGENERON PHARMACEUTICALS INC stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC and suggest that you do with its stocks.
REGN reached its all-time high on Jul 12, 2024 with the price of 1,093.35 USD, and its all-time low was 680.10 USD and was reached on Feb 14, 2025. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
REGN stock is 56.26% volatile and has beta coefficient of 0.76. Track REGENERON PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC there?
Today REGENERON PHARMACEUTICALS INC has the market capitalization of ‪74.34 B‬, it has decreased by −7.15% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 12.07 USD per share, whereas the estimation was 11.28 USD resulting in a 6.98% surprise. The estimated earnings for the next quarter are 9.55 USD per share. See more details about REGENERON PHARMACEUTICALS INC earnings.
REGENERON PHARMACEUTICALS INC revenue for the last quarter amounts to ‪3.79 B‬ USD, despite the estimated figure of ‪3.74 B‬ USD. In the next quarter, revenue is expected to reach ‪3.43 B‬ USD.
REGN net income for the last quarter is ‪917.70 M‬ USD, while the quarter before that showed ‪1.34 B‬ USD of net income which accounts for −31.55% change. Track more REGENERON PHARMACEUTICALS INC financial stats to get the full picture.
REGENERON PHARMACEUTICALS INC dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 19, 2025, the company has ‪15.11 K‬ employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC EBITDA is ‪4.60 B‬ USD, and current EBITDA margin is 32.79%. See more stats in REGENERON PHARMACEUTICALS INC financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.